HeartSciences Files Preliminary Proxy for All-Stock Merger with Fortitude Mining; Existing Shareholders to Own Just 5% of Combined Company
HSCS sits 45% above its 52-week low of $1.63.
Summary
HeartSciences' preliminary proxy details its all-stock merger with Fortitude Mining, leaving existing shareholders with just 5% of the combined company. The deal is a survival move for the cash-strapped med-tech firm, pivoting it into a Zcash mining operation.
Key Events · M&A and Partnerships · HSCS
-
Merger Agreement Amended
The merger agreement was amended on July 27, 2026, to change shareholder written consent requirements, clarify redemption mechanics, and adjust consideration for any pre-closing reverse stock split.
-
Extreme Dilution for Existing Holders
Upon closing, existing HeartSciences equityholders will own approximately 5% of the combined company's voting and economic interests, with Fortitude Seller holding ~95%.
-
Fairness Opinion Obtained
Houlihan Capital provided a fairness opinion to the special committee, concluding the aggregate consideration is fair from a financial point of view to HeartSciences shareholders.
-
Reverse Stock Split Proposed
Shareholders will vote on a reverse stock split at a ratio between 1-for-2 and 1-for-5 to help meet Nasdaq initial listing requirements for the combined company.
Analysis · HSCS · Industrial Applications And Services
HeartSciences has filed its preliminary proxy statement for the proposed all-stock merger with Fortitude Mining Holdings, a Zcash mining platform. The deal, first announced on June 23, 2026, would result in Fortitude Seller owning approximately 95% of the voting interests of the combined company, with existing HeartSciences shareholders retaining only about 5%. The proxy reveals an amended merger agreement, a fairness opinion from Houlihan Capital, and a slate of proposals including a reverse stock split and charter amendments. For HeartSciences, a company with a going concern warning, minimal cash, and a Nasdaq listing at risk, this merger represents a lifeline — but at the cost of extreme dilution for current holders. The combined entity would pivot from AI-enhanced electrocardiography to digital asset mining, with Fortitude's $86.8M in revenue and $10.5M in EBITDA (per recent filings) becoming the core business. The special meeting date is not yet set, but the board unanimously recommends approval.
At the time of this filing, HSCS was trading at $2.36 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $9.9M. The 52-week trading range was $1.63 to $4.30. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.